Bio­phar­ma stocks take a beat­ing as eco­nom­ic tur­moil takes its toll — but some play­ers with coro­n­avirus ef­forts un­der­way are up

The Bio­gen coro­n­avirus out­break has left most of its staff work­ing from home — and it’s been no help for its share price. The stock …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.